Differential Effects of Cyclosporin and Etanercept Treatment on Various Pathologic Parameters in a Murine Model of Irradiation-Induced Mucositis

Current Therapeutic Research - Clinical and Experimental

Volumn 73, Issue 4-5, 2012, Pages 150-164

  Tung, David ^a   Cheung, Peter H ^a   Wilson, James ^b   Tudor, Gregory ^b   Booth, Catherine ^b   Saha, Saurabh ^a  

^a BioMed Valley Discoveries   (United States)

^b Epistem Ltd   (United Kingdom)

Author keywords

Cyclosporin; Etanercept; Inflammation; Irradiation; Mucositis

Indexed keywords

CYCLOSPORIN; ETANERCEPT; PHOSPHATE BUFFERED SALINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; ENTERITIS; MALE; MOUSE; MUCOSA INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIATION EXPOSURE; RADIATION INJURY; SMALL INTESTINE MUCOSA; WEIGHT REDUCTION;

EID: 84865539637     PISSN: 0011393X     EISSN: 18790313     Source Type: Journal    
DOI: 10.1016/j.curtheres.2012.06.002     Document Type: Article

References (45)

1. Papa S., Bubici C., Zazzeroni F., et al. The NF-kappaB-mediated control of the JNK cascade in the antagonism of programmed cell death in health and disease. Cell Death Diff 2006, 13:712-729.
2. Sonis S.T. Pathobiology of mucositis. Semin Oncol Nurs 2004, 20:11-15.
3. Pico J.L., Avila-Garavito A., Naccache P. Mucositis: its occurrence, consequences, and treatment in the oncology setting. Oncologist 1998, 3:446-451.
4. Logan R.M., Gibson R.J., Bowen J.M., et al. Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol 2008, 62:33-41.
5. Sonis S.T. Pathobiology of oral mucositis: novel insights and opportunities. J Support Oncol 2007, 5:3-11.
6. Franko A.J., Sharplin J., Ghahary A., Barcellos-Hoff M.H. Immunohistochemical localization of transforming growth factor beta and tumor necrosis factor alpha in the lungs of fibrosis-prone and "non-fibrosing" mice during the latent period and early phase after irradiation. Radiat Res 1997, 147:245-256.
7. Johnston C.J., Piedboeuf B., Rubin P., et al. Early and persistent alterations in the expression of interleukin-1 alpha, interleukin-1 beta and tumor necrosis factor alpha mRNA levels in fibrosis-resistant and sensitive mice after thoracic irradiation. Radiat Res 1996, 145:762-767.
8. Bertazza L., Mocellin S. The dual role of tumor necrosis factor (TNF) in cancer biology. Curr Med Chem 2010, 17:3337-3352.
9. Bertazza L., Mocellin S. Tumor necrosis factor (TNF) biology and cell death. Front Biosci 2008, 13:2736-2743.
10. Zhang M., Qian J., Xing X., et al. Inhibition of the tumor necrosis factor-alpha pathway is radioprotective for the lung. Clin Cancer Res 2008, 14:1868-1876.
11. Matsushima Y., Baba T. The in vivo effect of cyclosporine A on macrophages. J Exp Pathol 1990, 5:39-48.
12. Hess A.D., Esa A.H., Colombani P.M. Mechanisms of action of cyclosporine: effect on cells of the immune system and on subcellular events in T cell activation. Transplant Proc 1988, 20:29-40.
13. Colombani P.M., Hess A.D. T-lymphocyte inhibition by cyclosporine. Potential mechanisms of action. Biochem Pharmacol 1987, 36:3789-3793.
14. Bunjes D., Hardt C., Rollinghoff M., Wagner H. Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2. Eur J Immunol 1981, 11:657-661.
15. Garcia J.E., Lopez A.M., de Cabo M.R., et al. Cyclosporin A decreases human macrophage interleukin-6 synthesis at post-transcriptional level. Mediators Inflamm 1999, 8:253-259.
16. Chiara M.D., Bedoya F., Sobrino F. Cyclosporin A inhibits phorbol ester-induced activation of superoxide production in resident mouse peritoneal macrophages. Biochem J 1989, 264:21-26.
17. Palay D.A., Cluff C.W., Wentworth P.A., Ziegler H.K. Cyclosporine inhibits macrophage-mediated antigen presentation. J Immunol 1986, 136:4348-4353.
18. Manca F., Fenoglio D., Kunkl A., et al. Effect of cyclosporine on the antigen-presenting function of human and murine accessory cells. Transplantation 1988, 46(Suppl):40S-43S.
19. Manca F., Kunkl A., Celada F. Inhibition of the accessory function of murine macrophages in vitro by cyclosporine. Transplantation 1985, 39:644-649.
20. Drath D.B., Kahan B.D. Alterations in rat pulmonary macrophage function by the immunosuppressive agents cyclosporine, azathioprine, and prednisolone. Transplantation 1983, 35:588-592.
21. Whisler R.L., Lindsey J.A., Proctor K.V., et al. Characteristics of cyclosporine induction of increased prostaglandin levels from human peripheral blood monocytes. Transplantation 1984, 38:377-381.
22. Letari O., Booth C., Bonazzi A., et al. Efficacy of CR3294, a new benzamidine derivative, in the prevention of 5-fluorouracil-induced gastrointestinal mucositis and diarrhea in mice. Cancer Chemother Pharmacol 2010, 66:819-827.
23. Tung D., Cheung P., Tudor G., et al. In vivo effects of immunomodulators in a murine model of fluorouracil-induced mucositis. Curr Ther Res 2011, 72:262-272.
24. Keefe D.M., Cummins A.G., Dale B.M., et al. Effect of high-dose chemotherapy on intestinal permeability in humans. Clin Sci (Lond) 1997, 92:385-389.
25. Keefe D.M., Brealey J., Goland G.J., Cummins A.G. Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut 2000, 47:632-637.
26. Maj J.G., Paris F., Haimovitz-Friedman A., et al. Microvascular function regulates intestinal crypt response to radiation. Cancer Res 2003, 63:4338-4341.
27. Dubois A., Walker R.I. Prospects for management of gastrointestinal injury associated with the acute radiation syndrome. Gastroenterology 1988, 95:500-507.
28. Dent P., Yacoub A., Fisher P.B., et al. MAPK pathways in radiation responses. Oncogene 2003, 22:5885-5896.
29. Xun C.Q., Thompson J.S., Jennings C.D., et al. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 1994, 83:2360-2367.
30. Hong J.H., Chiang C.S., Tsao C.Y., et al. Rapid induction of cytokine gene expression in the lung after single and fractionated doses of radiation. Int J Radiat Biol 1999, 75:1421-1427.
31. Zhang X., Mosser D.M. Macrophage activation by endogenous danger signals. J Pathol 2008, 214:161-178.
32. Maeng H.G., Kim D.N., Cho S.K., et al. Altered immune cell proportions in the radiodermatitis induced hairless mice-1 (HR-1). J Radiat Res (Tokyo) 2006, 47:9-17.
33. Bonan P.R., Kaminagakura E., Pires F.R., et al. Histomorphometry and immunohistochemical features of grade I (WHO) oral radiomucositis. Oral Dis 2007, 13:170-176.
34. Yeoh A.S., Gibson R.J., Yeoh E.E., et al. A novel animal model to investigate fractionated radiotherapy-induced alimentary mucositis: the role of apoptosis, p53, nuclear factor-kappaB, COX-1, and COX-2. Mol Cancer Ther 2007, 6:2319-2327.
35. Logan R.M., Stringer A.M., Bowen J.M., et al. The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev 2007, 33:448-460.
36. Haagen J., Krohn H., Rollig S., et al. Effect of selective inhibitors of inflammation on oral mucositis: preclinical studies. Radiother Oncol 2009, 92:472-476.
37. Huang X.W., Yang J., Dragovic A.F., et al. Antisense oligonucleotide inhibition of tumor necrosis factor receptor 1 protects the liver from radiation-induced apoptosis. Clin Cancer Res 2006, 12:2849-2855.
38. Losa Garcia J.E., Rodriguez F.M., Martin de Cabo M.R., et al. Evaluation of inflammatory cytokine secretion by human alveolar macrophages. Mediators Inflamm 1999, 8:43-51.
39. Tipton D.A., Pabst M.J., Dabbous M.K. Interleukin-1 beta- and tumor necrosis factor-alpha-independent monocyte stimulation of fibroblast collagenase activity. J Cell Biochem 1990, 44:253-264.
40. Rofe A.M., Philcox J.C., Haynes D.R., et al. Changes in plasma zinc, copper, iron, and hepatic metallothionein in adjuvant-induced arthritis treated with cyclosporin. Biol Trace Elem Res 1992, 34:237-248.
41. Andrievsky G.V., Bruskov V.I., Tykhomyrov A.A., Gudkov S.V. Peculiarities of the antioxidant and radioprotective effects of hydrated C60 fullerene nanostuctures in vitro and in vivo. Free Radic Biol Med 2009, 47:786-793.
42. Jindal A., Soyal D., Sancheti G., Goyal P.K. Radioprotective potential of Rosemarinus officinalis against lethal effects of gamma radiation: a preliminary study. J Environ Pathol Toxicol Oncol 2006, 25:633-642.
43. Parihar V.K., Prabhakar K.R., Veerapur V.P., et al. Anticlastogenic activity of morin against whole body gamma irradiation in Swiss albino mice. Eur J Pharmacol 2007, 557:58-65.
44. Hou B., Xu Z.W., Yang C.W., et al. Protective effects of inosine on mice subjected to lethal total-body ionizing irradiation. J Radiat Res (Tokyo) 2007, 48:57-62.
45. Ong Z.Y., Gibson R.J., Bowen J.M., et al. Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis. Radiat Oncol 2010, 5:22.